Inhibrx Inc (INBX)
34.34
-0.12
(-0.35%)
USD |
NASDAQ |
Apr 19, 15:36
Inhibrx Revenue (TTM): 1.80M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.80M |
| September 30, 2023 | 0.44M |
| June 30, 2023 | 0.599M |
| March 31, 2023 | 1.28M |
| December 31, 2022 | 2.178M |
| September 30, 2022 | 4.74M |
| June 30, 2022 | 6.97M |
| March 31, 2022 | 7.177M |
| December 31, 2021 | 7.125M |
| September 30, 2021 | 7.065M |
| Date | Value |
|---|---|
| June 30, 2021 | 10.38M |
| March 31, 2021 | 12.80M |
| December 31, 2020 | 12.81M |
| September 30, 2020 | 10.30M |
| June 30, 2020 | 5.267M |
| March 31, 2020 | 2.933M |
| December 31, 2019 | 9.093M |
| September 30, 2019 | 11.33M |
| June 30, 2019 | 13.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.44M
Minimum
Sep 2023
13.03M
Maximum
Jun 2019
6.701M
Average
7.065M
Median
Sep 2021
Revenue (TTM) Benchmarks
| Johnson & Johnson | 89.66B |
| Gilead Sciences Inc | 27.12B |
| Outlook Therapeutics Inc | -- |
| Axonics Inc | 366.38M |
| NovaBay Pharmaceuticals Inc | 14.73M |